| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Oct 26, 2026Next | Q3 2026 | — | 16.17 | 4.63 B |
Aug 31, 2026
The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtay
Aug 30, 2026
Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, following positive Phase 3 OPTIMA trial data on heterotopic ossification lesion reduction. Regeneron Pharmaceuticals shares trade at US$794.19 after a recent pullback, with the 7 day share price return down 4.78% and the 90 day share price return up 32.22%. The 1 year total shareholder return of 37.47% points to momentum that has built over a...
Aug 29, 2026
Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debilitating condition. Pasatru adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream. This kind of targeted drug development in rare diseases is part of a wider shift toward more data driven healthcare,...
Aug 27, 2026
The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, tendons, and ligaments, progressively restricting movement. In a 56-week Phase 3 trial involving 63 adults, the approved 3-milligram-per-kilogram dose reduced the number of […]
Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund’s Investor Class (SSHFX) and Institutional Class (SSHVX) rose 10.48% and 10.58% in the second quarter of 2026, trailing the Russell 1000 Value Index’s 13.87% and the S&P 500’s […]
Aug 26, 2026
Regeneron Pharmaceuticals has comfortably outperformed the S&P 500 over the past year, and Wall Street remains reasonably bullish on the company’s long-term growth prospects.
Aug 25, 2026
Veeva Systems (NYSE: VEEV) today announced that Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally. With Vault CRM, Regeneron plans to generate Commercial Evidence from AI-powered field engagement, uncovering hidden barriers to treatment adoption and ensuring their medicines can reach eligible patients in need.
Regeneron Pharmaceuticals, Inc. stock outlook: Eylea pressure eases as Dupixent jumps; FDA OKs Pasatru. Read why REGN stock is a buy.
Aug 24, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 19.2%. Currently, Regeneron Pharmaceuticals has a market
Aug 21, 2026
Oil transportation stock Frontline is at a new high in Friday's stock market. Advantest, Regeneron Pharma and Magna International are also at highs.
Aug 20, 2026
REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.
Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.
In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...
Regeneron Pharmaceuticals stock has delivered a 43.0% return over the past year, yet the broader valuation checks point to a more mixed picture rather than a clear bargain or obvious overpricing. With recent partnership activity and pipeline progress in the spotlight, investors are weighing how much of that is already reflected in the current US$840.84 share price. The 43.0% one year return signals that the market has already repriced Regeneron Pharmaceuticals positively. The key issue for...
Aug 19, 2026
TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026Morgan Stanley 24th Annual Global Healthcare Conference at 1:05 p.m. ET on Monday, September 14, 2026Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum at 10:30 a.m. ET on Wednesday, September 23, 2026 The sessions may be accessed fr
